CABIO(SH:688089) Chang Jiang Shang Bao·2025-12-18 01:25Core Insights - Company has focused on emerging products such as SA (Sialic Acid) and HMOs (Human Milk Oligosaccharides) while maintaining its core product line [1][2] - The company reported a revenue of 430 million yuan for the first three quarters of 2025, a year-on-year increase of 10.56%, and a net profit of 130 million yuan, up 54.18% year-on-year, indicating a significant profit growth outpacing revenue growth [1] - The company aims to expand its market presence in infant formula, animal nutrition, and personal care sectors through a strategy termed "one main and two wings" [1][2] Company Strategy - The company is enhancing its product offerings in the infant formula market by promoting algal oil DHA as a substitute for fish oil DHA and deepening cooperation on HMOs [2] - In the pet nutrition sector, the company employs a strategy of "technology research + brand marketing + supply chain management" to enhance product innovation and competitiveness [3] - In the beauty and personal care sector, the company leverages synthetic biology and innovative technologies to rapidly screen and validate new cosmetic raw materials [3] Market Position - The company is a leader in the microbial synthesis nutrient sector in China, with key products including ARA, DHA, and β-carotene, widely used in infant formula, health foods, animal nutrition, and personal care [1] - The domestic and international milk powder markets continue to provide favorable conditions for the company's stable performance [1] - The approval of HMOs as new raw materials for infant formula by the National Health Commission is expected to accelerate the application of these products in the infant nutrition sector [2]